Latest Ratios: P/E Ratio 6.0x · EV/EBITDA 6.8x · ROE 21.6%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26.9B | $15.4B | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $46.5B | $116.0B | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | 5.98 | 1.39 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.29 | 0.03 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.27 | 0.29 | — | — | — | — | — | — | — | — | — |
| P/FCF | 33.47 | 3.73 | — | — | — | — | — | — | — | — | — |
| P/OCF | 8.92 | 0.99 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.25 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 6.77 | 3.29 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 10.55 | 5.13 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 28.10 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.8% | 12.8% | 15.1% | 10.9% | 15.9% | 18.9% | 16.7% | 15.6% | 14.5% | 14.6% | 12.5% |
| Operating Margin | 4.8% | 4.8% | 5.7% | 1.5% | 6.6% | 9.2% | 7.6% | 6.6% | 3.9% | 4.1% | 3.9% |
| Net Profit Margin | 2.4% | 2.4% | 2.3% | -0.3% | 4.1% | 5.9% | 1.7% | 3.0% | 0.0% | 0.3% | 0.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.6% | 21.6% | 19.8% | -2.2% | 32.5% | 46.5% | 12.1% | 20.1% | 0.1% | 2.2% | 0.9% |
| ROA | 4.4% | 4.4% | 4.2% | -0.5% | 7.6% | 11.4% | 3.2% | 5.0% | 0.0% | 0.5% | 0.2% |
| ROIC | 11.2% | 11.2% | 12.5% | 2.9% | 14.1% | 22.1% | 17.0% | 12.7% | 7.3% | 7.1% | 6.7% |
| ROCE | 12.4% | 12.4% | 14.1% | 3.4% | 16.8% | 24.7% | 18.5% | 14.1% | 8.3% | 9.0% | 8.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.40 | 2.40 | 2.68 | 2.35 | 2.10 | 2.17 | 1.70 | 1.84 | 2.04 | 2.18 | 2.39 |
| Debt / EBITDA | 3.57 | 3.57 | 4.03 | 7.85 | 2.95 | 2.43 | 2.76 | 3.22 | 4.78 | 5.10 | 5.09 |
| Net Debt / Equity | — | 1.92 | 1.99 | 1.88 | 1.83 | 1.68 | 1.25 | 1.53 | 1.72 | 1.73 | 1.99 |
| Net Debt / EBITDA | 2.85 | 2.85 | 2.99 | 6.27 | 2.58 | 1.88 | 2.03 | 2.68 | 4.03 | 4.05 | 4.24 |
| Debt / FCF | — | 24.37 | 6.47 | 22.02 | 43.30 | 6.78 | 3.06 | 5.22 | 10.43 | 21.65 | 250.62 |
| Interest Coverage | 2.46 | 2.46 | 15.60 | 3.44 | 19.28 | 34.51 | 5.65 | 3.24 | 2.01 | 1.49 | 2.12 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.60 | 1.60 | 1.47 | 1.64 | 1.44 | 1.40 | 1.48 | 1.47 | 1.71 | 1.24 | 1.02 |
| Quick Ratio | 0.91 | 0.91 | 0.90 | 0.95 | 0.75 | 0.84 | 0.93 | 0.86 | 1.04 | 0.81 | 0.65 |
| Cash Ratio | 0.41 | 0.41 | 0.48 | 0.46 | 0.24 | 0.39 | 0.48 | 0.35 | 0.41 | 0.40 | 0.28 |
| Asset Turnover | — | 1.90 | 1.65 | 1.76 | 1.85 | 1.75 | 1.65 | 1.62 | 1.59 | 1.50 | 1.66 |
| Inventory Turnover | 9.42 | 9.42 | 8.63 | 9.83 | 8.53 | 8.66 | 9.91 | 9.95 | 10.71 | 11.19 | 12.14 |
| Days Sales Outstanding | — | 22.78 | 20.25 | 16.47 | 19.24 | 20.01 | 18.91 | 19.87 | 19.40 | 20.88 | 20.54 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 13.2% | 57.2% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | 79.4% | 79.4% | 46.1% | — | 28.0% | 34.8% | 31.3% | 0.1% | 503.5% | 17.5% | 471.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 16.7% | 72.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 3.0% | 26.8% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 2.3% | 20.7% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 15.5% | 77.9% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $1.1B | $2.2B | $2.2B | $2.3B | $2.5B | $2.7B | $2.7B | $2.7B | $2.8B | $2.7B |
High leverage amid cyclicality
According to current market data, JBS trades at a TTM P/E of 6.08 and a P/S of 0.30, suggesting that investors are heavily discounting the company's earnings potential due to the inherent volatility of the global protein cycle and the company's complex, debt-heavy capital structure.
The low valuation multiples relative to peers like Hormel Foods suggest the market views JBS as a commodity-exposed processor rather than a branded consumer goods company. This valuation gap may persist until the company demonstrates a sustained ability to decouple its earnings from the volatile US cattle cycle and successfully executes its dual-listing strategy.
Based on reported financial figures, JBS's ROIC has languished at 1.2% in 2026Q1, a significant decline from the 5.4% peak in 2025Q3, indicating that the company is struggling to generate adequate returns on its massive invested capital base during this period of industry-wide margin compression.
The sharp decay in ROIC highlights the difficulty of maintaining profitability in a capital-intensive, low-margin industry when input costs rise. Investors should monitor whether management can improve asset utilization or if the current return profile is a permanent feature of the company's global, multi-protein operating model.
As reported in recent quarterly filings, JBS's cash conversion cycle expanded to 29 days in 2026Q1 from 14 days in 2025Q4, revealing that the company's working capital efficiency is highly sensitive to inventory management and the timing of payments across its diverse global protein segments.
The rapid fluctuation in the CCC suggests that JBS lacks the working capital stability of more vertically integrated or less commodity-dependent peers. This volatility forces the company to maintain higher liquidity buffers, which in turn complicates its ability to optimize cash deployment during cyclical downturns.
According to the latest balance sheet data, JBS maintains a D/E ratio of 2.55 and an interest coverage ratio that has fallen to 1.00 in 2026Q1, indicating that the company's debt service capacity is currently at a critical inflection point given the prevailing interest rate environment.
The high leverage ratio relative to peers like Tyson Foods suggests that JBS has limited room for error in its operational execution. The narrowing interest coverage ratio warrants close investigation, as any further decline in operating income could significantly increase refinancing risk and constrain future capital allocation options.
As noted in industry research, the P/E ratio is frequently misapplied to JBS because it fails to account for the non-cash distortions caused by biological asset fair value adjustments, which can artificially inflate or deflate reported net income in any given quarter.
Analysts should instead focus on EV/EBITDA or normalized free cash flow to better assess the company's underlying earning power. Relying on P/E in a commodity-driven business model obscures the true cash-generative capacity of the operations and leads to flawed comparisons with less cyclical, non-protein-based food companies.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JBS stock.
JBS N.V.'s current P/E ratio is 6.0x. The historical average is 1.4x. This places it at the 100th percentile of its historical range.
JBS N.V.'s current EV/EBITDA is 6.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.3x.
JBS N.V.'s return on equity (ROE) is 21.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 14.8%.
Based on historical data, JBS N.V. is trading at a P/E of 6.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
JBS N.V.'s current dividend yield is 13.23% with a payout ratio of 79.4%.
JBS N.V. has 12.8% gross margin and 4.8% operating margin.
JBS N.V.'s Debt/EBITDA ratio is 3.6x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.